Stage 1 prostate cancer has a very high 5-year survival rate of over 99%.
Approximately 19% of men diagnosed with prostate cancer in New Zealand fall into the low-risk group, which includes Stage 1.
For low-risk cancer in New Zealand, around 80% of patients are managed with active surveillance.
Stage 1 prostate cancer means the cancer is small and contained entirely within the prostate. At this stage:
- The cancer cannot be felt during a digital rectal exam
- The cancer is microscopic and only found through a biopsy
- PSA levels are usually below 10 ng/mL
- The Gleason score is typically 6 or lower
Stage 1 prostate cancer is part of the "low-risk" category and has an excellent prognosis in New Zealand, with many treatment options available.
In New Zealand, most Stage 1 prostate cancers are detected through PSA blood tests, followed by either transperineal or transrectal biopsies. Transperineal biopsy (where the needle passes through the skin between the scrotum and rectum) is now the preferred method in New Zealand due to lower risk of complications.